Aurobindo Pharma's Stock Surges 5% to 52-Week High Ahead of Share Buyback Decision

Aurobindo Pharma, a leading pharmaceutical company, saw its share price rise by more than 5% on Monday, reaching a 52-week high. This surge in stock price comes as the company prepares for a crucial board meeting on July 18, 2024, where a share buyback proposal will be discussed.

The stock opened at ₹1,360.00, slightly higher than the previous close of ₹1,326.85, and quickly climbed to an intraday high of ₹1,394.35 on the NSE. The announcement of the board meeting has fueled investor optimism, leading to significant gains in the company's share price.

Also Read | Deepinder Goyal Becomes Billionaire as Zomato's Stock Soars 83% in 2024

Driving Factors Behind the Surge

Share Buyback Proposal

The primary driver of Aurobindo Pharma's recent stock rally is the anticipation of a share buyback. In a statement to the exchanges, the company announced that its board would meet to consider a proposal for the buyback of fully paid-up equity shares. This move is in line with the applicable provisions under the Companies Act, 2013, and is expected to positively impact the company's share price by reducing the number of outstanding shares, thus increasing the value of remaining shares.

Improving Earnings Prospects

Aurobindo Pharma's share price has gained nearly 90% over the past year, bolstered by improving earnings and a positive outlook. The company has overcome concerns related to pricing pressure in the US market, its largest revenue contributor. Additionally, Aurobindo Pharma has seen strong performance in Europe, its second-largest market, which has further boosted investor confidence.

Axis Securities predicts that Aurobindo Pharma's Q1FY25 results will surpass industry growth, driven by a superior product portfolio and a robust pipeline. In Q4FY24, the company's US revenue increased by 20.4% year-on-year to $432 million, contributing more than 47% to overall revenues. Analysts expect US sales to continue their momentum in Q1FY25, with stable gross margins supported by consistent Active Pharma Ingredients (API) prices.

Motilal Oswal Financial Services (MOFSL) also projects a 12% year-on-year growth in US sales for Q1FY25, reaching $451 million. This growth is expected to be driven by key product launches and despite the temporary shutdown of the Eugia unit-3 manufacturing facility.

In Europe, Aurobindo Pharma reported a revenue of €203 million in Q4FY24, accounting for 24.2% of consolidated revenue and marking an 8% year-on-year growth. MOFSL estimates a 7.5% year-on-year increase in European sales for Q1FY25, reaching ₹1,970 crore, driven by expansion into new markets and differentiated product offerings.

Technical Analysis and Market Sentiment

Ruchit Jain, Lead Research Analyst at 5paisa, noted that Aurobindo Pharma's share price has formed a Higher Top Higher Bottom structure, indicating an uptrend. The 20-day Exponential Moving Average (DEMA) at ₹1,206 serves as near-term support, while resistance is anticipated around the ₹1,245-₹1,250 zone. Trendlyne data shows that Aurobindo Pharma's stock price has increased by 173.8% over the last year, significantly outpacing its sector by 129.31%.

Kushal Gandhi, Technical Analyst at StoxBox, highlighted that Aurobindo Pharma's share price has surged by over 450% since its all-time low in July 2022. Following a bullish breakout from its previous all-time high of ₹1,169, the stock entered a brief accumulation phase, suggesting potential for further bullish momentum. With improving Earnings Per Share (EPS), high relative price strength, and strong buyer demand, analysts recommend buying Aurobindo Pharma with a target price of ₹1,265 and a stop loss of ₹1,211.

Strategic Moves and Financial Performance

Aurobindo Pharma's decision to consider a share buyback is part of a broader strategy to enhance shareholder value. This follows an earlier successful earnings report, where the company demonstrated significant growth across key markets. The introduction of platform fees, higher average order values, increased topline, and effective cost control measures have contributed to a strong financial performance.

The company's robust performance in several key areas has driven its revenue growth. In Q4FY24, Aurobindo Pharma's revenue increased by 73.3% year-on-year to ₹3,562 crore. The introduction of platform fees, higher average order values, increased topline, and effective cost control measures contributed to an EBITDA of ₹86 crore.

Brokerage and Market Analysis

Geojit Financial Services has reiterated its BUY recommendation on Aurobindo Pharma, citing significant growth potential in the company's rapid commerce and meal delivery segments. The brokerage firm highlights Aurobindo Pharma's expanding customer base, increasing order frequency, growing network of delivery partners, and operational leverage as key drivers of its bright prospects.

After the release of its Q4 earnings, Aurobindo Pharma has successfully scaled its operations, driven by growth across all segments and improved profitability. The company anticipates strong performance in its food delivery business, driven by scale improvements, a growing customer base, increased order frequency, and operational efficiency. The quick commerce business is also expected to thrive with the addition of new stores and rising customer demand.

Also Read | Baroda Cricket Association (BCA) to Launch Women’s Cricket Tournament to Nurture Talent

Conclusion

Aurobindo Pharma's recent stock surge to a 52-week high, driven by the upcoming board meeting on a share buyback proposal, reflects strong investor confidence and the company's robust financial performance. With a positive earnings outlook and strategic initiatives to enhance shareholder value, Aurobindo Pharma is well-positioned for continued growth and success in the pharmaceutical industry. Investors and stakeholders can look forward to sustained growth and profitability as the company continues to innovate and expand its market presence.

For more in-depth analysis and updates on Aurobindo Pharma's stock performance, stay tuned to official reports and expert insights.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst & Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX & Upstox.